A Clinical Case of Successful Treatment of HER2-Low Disseminated Breast Cancer with Trastuzumab Deruxtecan
نویسندگان
چکیده
Анти-HER2 терапия на основе трастузумаба является стандартом лечения больных HЕR2-позитивными опухолями. Внедрение таргетной терапии позволило кардинально улучшить прогноз и качество жизни HER2-позитивным раком молочной железы (HER2+ РМЖ). В данном клиническом случае представлен первый опыт Иркутской области эффективного препаратом трастузумаб дерукстеканом пациентки с прогрессирующим диссеминированным гормонопозитивным низкой экспрессией HER2 (HER2-Low) практически исчерпанными возможностями лекарственного противоопухолевого лечения. Аналогичная эффективность дерукстекана доказана у подобного контингента в исследовании DESTINY-Breast04 (NCT03734029).
منابع مشابه
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
The HER2-targeted therapy trastuzumab is widely used for the treatment of patients with metastatic breast tumors overexpressing HER2. However, an objective response is observed in only 12% to 24% of patients treated with trastuzumab as a single agent and initial responders regress in <6 months (1-3). The reason for the clinical failure of trastuzumab in this setting remains unclear. Here we sho...
متن کاملHER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
PURPOSE The efficacy of trastuzumab in Chinese breast cancer (BC) patients has rarely been reported. This study was designed to compare the clinical outcomes of HER2-positive BC patients receiving or not receiving trastuzumab treatment and HER2-negative BC patients. PATIENTS AND METHODS This study involved three groups of patients. The first group was 115 human epidermal growth factor recepto...
متن کاملPre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease
Studies from this laboratory have demonstrated the potential of targeting HER2 for therapeutic and imaging applications with medically relevant radionuclides. To expand the repertoire of trastuzumab as a radioimmunoconjugate (RIC) vector, use of (177)Lu was investigated. The combination of a 6.7 d half-life, lower energy β(-)-emissions (500 keV max; 130 keV ave), and an imagable γ-emission make...
متن کاملSuccessful Treatment of HER2-neu–positive Breast Cancer With Paclitaxel and Trastuzumab Supplemented With Turkey Tail Mushrooms and Community Support
Case report The patient, “PS,” was an 83-year-old white female who presented at Bastyr University, Kenmore, Washington, and Swedish Cancer Institute, Seattle, in June 2009 with advanced, metastatic inflammatory breast cancer. The patient had a large mass in her right breast with significant lymphedema and swelling, redness, and dermal invasion. The tumor had invaded the chest wall, right should...
متن کاملAdjuvant trastuzumab in HER2-positive breast cancer.
BACKGROUND Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. METHODS We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Voprosy onkologii
سال: 2023
ISSN: ['0507-3758']
DOI: https://doi.org/10.37469/0507-3758-2023-69-4-757-760